- Stocks
- Healthcare
- NASDAQ: BEAT

Price (delayed)

$71.85

Market cap

$2.46B

P/E Ratio

135.57

Dividend/share

N/A

EPS

$0.53

Enterprise value

$2.53B

The company's quick ratio rose by 20% YoY and by 11% QoQ

The debt has contracted by 19% YoY

The stock's price to earnings (P/E) is 197% more than its 5-year quarterly average of 45.7 and 101% more than its last 4 quarters average of 67.3

The net income has dropped by 54% year-on-year and by 8% since the previous quarter

What are the main financial stats of BEAT

Market
Valuations
Earnings

Shares outstanding

34.26M

Market cap

$2.46B

Enterprise value

$2.53B

Price to earnings (P/E)

135.57

Price to book (P/B)

6.2

Price to sales (P/S)

5.62

EV/EBIT

66.51

EV/EBITDA

30.34

EV/Sales

5.76

Revenue

$438.83M

EBIT

$38.04M

EBITDA

$83.39M

Free cash flow

$71.48M

Per share
Balance sheet
Liquidity

EPS

$0.53

Free cash flow per share

$2.08

Book value per share

$11.6

Revenue per share

$12.79

TBVPS

$8.81

Total assets

$737.1M

Total liabilities

$340.71M

Debt

$158.33M

Equity

$396.38M

Working capital

$122.37M

Debt to equity

0.4

Current ratio

2.8

Quick ratio

2.63

Net debt/EBITDA

0.82

Margins
Efficiency
Dividend

EBITDA margin

19%

Gross margin

61.7%

Net margin

4%

Operating margin

9.2%

Return on assets

2.5%

Return on equity

4.6%

Return on invested capital

11.7%

Return on capital employed

5.7%

Return on sales

8.7%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Biotelemetry stock price performed over time

Intraday

-0.07%

1 week

-0.11%

1 month

-0.51%

1 year

32.76%

YTD

-0.32%

QTD

-0.32%

How have Biotelemetry's revenue and profit performed over time

Revenue

$438.83M

Gross profit

$270.94M

Operating income

$40.3M

Net income

$17.68M

Gross margin

61.7%

Net margin

4%

The net margin has plunged by 56% YoY and by 9% from the previous quarter

The net income has dropped by 54% year-on-year and by 8% since the previous quarter

The operating margin has contracted by 32% YoY and by 8% from the previous quarter

The operating income has declined by 31% year-on-year and by 7% since the previous quarter

What is Biotelemetry's growth rate over time

What is Biotelemetry stock price valuation

P/E

135.57

P/B

6.2

P/S

5.62

EV/EBIT

66.51

EV/EBITDA

30.34

EV/Sales

5.76

The stock's price to earnings (P/E) is 197% more than its 5-year quarterly average of 45.7 and 101% more than its last 4 quarters average of 67.3

BEAT's EPS has shrunk by 54% YoY and by 7% QoQ

BEAT's P/B is 59% above its last 4 quarters average of 3.9 and 27% above its 5-year quarterly average of 4.9

The equity is up by 10% year-on-year and by 3.3% since the previous quarter

The price to sales (P/S) is 65% more than the last 4 quarters average of 3.4 and 56% more than the 5-year quarterly average of 3.6

How efficient is Biotelemetry business performance

Biotelemetry's return on equity has shrunk by 60% YoY and by 12% QoQ

Biotelemetry's ROA has plunged by 58% YoY and by 7% from the previous quarter

BEAT's return on invested capital is down by 38% year-on-year and by 6% since the previous quarter

BEAT's ROS is down by 35% YoY and by 6% QoQ

What is BEAT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for BEAT.

How did Biotelemetry financials performed over time

Biotelemetry's total assets is 116% higher than its total liabilities

The company's quick ratio rose by 20% YoY and by 11% QoQ

BEAT's current ratio is up by 14% year-on-year and by 11% since the previous quarter

The debt is 60% less than the equity

The company's debt to equity fell by 26% YoY and by 2.4% QoQ

The equity is up by 10% year-on-year and by 3.3% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.